Baseline MTV by treatment arm and characteristics
| Treatment arm or characteristic . | n/N . | Median MTV (range), mL . | Descriptive P value∗ . |
|---|---|---|---|
| Treatment arm | |||
| Axi-cel | 175†/180 | 228.66 (2.3-16 669.3) | .66 |
| Standard care | 165/179 | 231.90 (0.04-2 811.2) | |
| Age, y | |||
| <65 | 235/250 | 256.57 (0.04-16 669.3) | <.01 |
| ≥65 | 105/109 | 176.71 (6.8-4 101.8) | |
| Molecular subgroup, per central laboratory | |||
| GCB | 202/208 | 229.45 (3.5-16 669.3) | .55 |
| Non-GCB | 53/56 | 242.60 (6.9-5 488.5) | |
| Disease type, per central laboratory | |||
| HGBL | 54/57 | 307.71 (8.5-6 823.5) | .31 |
| Non-HGBL | 251/256 | 228.48 (0.04-16 669.3) | |
| LDH | |||
| Elevated | 185/195 | 371.17 (2.3-16 669.3) | <.01 |
| Normal | 155/164 | 126.96 (0.04-3 712.8) | |
| Response to first-line therapy at randomization | |||
| Primary refractory | 252/265 | 236.88 (0.04-16 669.3) | .64 |
| Relapse ≤12 mo after completion of 1L therapy | 87/92 | 215.33 (3.6-5 317.7) | |
| CD19 positive on IHC staining | |||
| Yes | 270/278 | 237.92 (0.04-13 527.0) | .86 |
| No | 25/25 | 248.89 (3.6-16 669.3) | |
| CD19 H-score | |||
| Less than or equal to median‡ | 149/152 | 241.75 (0.04-16 669.3) | .79 |
| Greater than median | 146/151 | 229.72 (2.3-13 527.0) |
| Treatment arm or characteristic . | n/N . | Median MTV (range), mL . | Descriptive P value∗ . |
|---|---|---|---|
| Treatment arm | |||
| Axi-cel | 175†/180 | 228.66 (2.3-16 669.3) | .66 |
| Standard care | 165/179 | 231.90 (0.04-2 811.2) | |
| Age, y | |||
| <65 | 235/250 | 256.57 (0.04-16 669.3) | <.01 |
| ≥65 | 105/109 | 176.71 (6.8-4 101.8) | |
| Molecular subgroup, per central laboratory | |||
| GCB | 202/208 | 229.45 (3.5-16 669.3) | .55 |
| Non-GCB | 53/56 | 242.60 (6.9-5 488.5) | |
| Disease type, per central laboratory | |||
| HGBL | 54/57 | 307.71 (8.5-6 823.5) | .31 |
| Non-HGBL | 251/256 | 228.48 (0.04-16 669.3) | |
| LDH | |||
| Elevated | 185/195 | 371.17 (2.3-16 669.3) | <.01 |
| Normal | 155/164 | 126.96 (0.04-3 712.8) | |
| Response to first-line therapy at randomization | |||
| Primary refractory | 252/265 | 236.88 (0.04-16 669.3) | .64 |
| Relapse ≤12 mo after completion of 1L therapy | 87/92 | 215.33 (3.6-5 317.7) | |
| CD19 positive on IHC staining | |||
| Yes | 270/278 | 237.92 (0.04-13 527.0) | .86 |
| No | 25/25 | 248.89 (3.6-16 669.3) | |
| CD19 H-score | |||
| Less than or equal to median‡ | 149/152 | 241.75 (0.04-16 669.3) | .79 |
| Greater than median | 146/151 | 229.72 (2.3-13 527.0) |
GCB, germinal center B-cell like; HGBL, high-grade B-cell lymphoma; IHC, immunohistochemistry.
Two-sided P values for 2-group comparisons were calculated using Wilcoxon rank sum test.
The initial presentation of these analyses31 inadvertently included data from a patient who was retreated with axi-cel. Those data were removed, and only data from randomized treatment were included.
Median CD19 H-score was 150.